Autoimmune & Rheumatology Clinical Trials Update: Week 23, 2026

Published June 5, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

This Phase 3 trial is testing ianalumab, a new antibody treatment, in patients with active systemic lupus erythematosus (SLE). The study explores two different dosing plans added to standard therapies, aiming to improve disease control and quality of life. With over 400 participants enrolled worldwide, this research could lead to an additional treatment option for managing SLE more effectively.

A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis

This completed Phase 3 trial investigated guselkumab, an antibody treatment given by injection, for adults with active psoriatic arthritis. By targeting joint inflammation and symptoms, guselkumab may reduce pain and improve physical function. The study included more than 700 participants across various countries, providing important information about this therapy’s safety and effectiveness.

Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis

This early phase trial tested itolizumab, a monoclonal antibody, in people with systemic lupus erythematosus, including those with active lupus nephritis affecting the kidneys. The treatment works differently from current options, aiming to better control the immune response while keeping side effects manageable. Enrollment is complete, and results from this multi-country study are now available, offering hope for new ways to manage lupus.

The PROACTIVE Study for Black Elders

This ongoing study focuses on a culturally tailored pain self-management program for Black adults aged 50 to 92 experiencing chronic musculoskeletal pain. The goal is to reduce pain that occurs during movement through non-drug methods. Recruiting in the United States, this trial could provide an important option for managing chronic pain among older adults in this community.

A Clinical Study to Evaluate the Efficacy of Native CT-II® in Individuals With Knee Osteoarthritis

This trial is examining Native CT-II®, a nutritional supplement, in adults with knee osteoarthritis to see if it improves joint health and reduces symptoms. Conducted in India with plans to enroll about 114 participants, the study offers the possibility of a treatment with fewer side effects than some current options. Results may help guide future care for those living with knee osteoarthritis.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.